NCT03380039: Phase 1 - Clinical Study of CAR-BCMA T Cells in Patients With RRMM

NCT03380039: Phase 1 - Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR-BCMA T cells in patients with BCMA-positive refractory or relapsed multiple myeloma.

Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Collaborator: CARsgen Therapeutics Co., Ltd.

ClinicalTrials.gov Identifier: NCT03380039

Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma

Click here for details on Clinicaltrials.gov

---

CART - BCMA : National Cancer Institute

Genetic: CAR-BCMA T cells

Drug: Fludarabine

Drug: Cyclophosphamide

---

703.Adoptive Immunotherapy: Mechanisms and New Approaches| November 13, 2019

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

https://doi.org/10.1182/blood-2019-126104

China, Shanghai

Xin Hua Hospital of Shanghai Jiao Tong University of Medicine Shanghai,

Shanghai, China, 200092